{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:22:22Z","timestamp":1790810542702,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod Biol Endocrinol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To study whether AMH levels were associated with miscarriage rates in index ART cycles undergoing fresh autologous transfers in PCOS and non-PCOS related\u00a0infertility.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In the SART CORS database 66,793 index cycles underwent fresh autologous embryo transfers with AMH values reported within the last 1-year between 2014 and 2016. Cycles that resulted in ectopic or heterotopic pregnancies, or\u00a0were performed for embryo\/oocyte banking were excluded.<\/jats:p>\n                <jats:p>Data were analyzed using Graphpad Prism-9. Odds ratios (OR) were calculated with 95% confidence intervals (CI) along with multivariate regression analysis adjusting for age, body mass index (BMI), and number of embryos transferred. Miscarriage rates were calculated as miscarriage per clinical pregnancies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the total 66,793 cycles, the mean AMH was 3.2\u00a0ng\/ml and were not associated with increased miscarriage rates for AMH\u2009&lt;\u20091\u00a0ng\/ml (OR 1.1, CI 0.9\u20131.4, <jats:italic>p\u2009=<\/jats:italic>\u20090.3). Of the 8,490 PCOS patients, the mean AMH was 6.1\u00a0ng\/ml and were not associated with increased miscarriage rates for AMH\u2009&lt;\u20091\u00a0ng\/ml (OR 0.8, CI 0.5\u20131.1, <jats:italic>p\u2009=<\/jats:italic>\u20090.2). Of the 58,303 non-PCOS patients, the mean AMH was 2.8\u00a0ng\/ml and there was a significant difference in miscarriage rates for AMH\u2009&lt;\u20091\u00a0ng\/ml (OR 1.2, CI 1.1\u20131.3, <jats:italic>p\u2009&lt;<\/jats:italic>\u20090.01). All findings were independent of age, BMI and number of embryos transferred. This statistical significance did not persist at higher thresholds of AMH. The overall miscarriage rate for all cycles, and cycles with and without PCOS were each 16%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The clinical utility of AMH continues to increase as more studies investigate its predictive abilities regarding reproductive outcomes. This study adds clarity to the mixed findings of prior studies that have examined the relationship between AMH and miscarriage in ART cycles.<\/jats:p>\n                <jats:p>AMH values of the PCOS population are higher than the non-PCOS. The elevated AMH associated with PCOS decreases its utility in predicting miscarriages in IVF cycles as it may be representing the number of developing follicles rather than oocyte quality in the PCOS patient population. The elevated AMH associated with PCOS may have skewed the data; removing this sub-population may have unmasked significance within the non-PCOS associated infertility.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>AMH\u2009&lt;\u20091\u00a0ng\/mL is an independent predictor of increased miscarriage rate in patients with non-PCOS infertility.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12958-023-01087-5","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T08:13:54Z","timestamp":1680682434000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["AMH predicts miscarriage in non-PCOS but not in PCOS related infertility ART cycles"],"prefix":"10.1186","volume":"21","author":[{"given":"Christopher","family":"Arkfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshef","family":"Tal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Seifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"issue":"6","key":"1087_CR1","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1210\/endrev\/bnab012","volume":"42","author":"N di Clemente","year":"2021","unstructured":"di Clemente N, Racine C, Pierre A, Taieb J. Anti-Mullerian Hormone in Female Reproduction. Endocr Rev. 2021;42(6):753\u201382. https:\/\/doi.org\/10.1210\/endrev\/bnab012.","journal-title":"Endocr Rev"},{"issue":"7","key":"1087_CR2","doi-asserted-by":"publisher","first-page":"e22024","DOI":"10.1371\/journal.pone.0022024","volume":"6","author":"TW Kelsey","year":"2011","unstructured":"Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WH. A validated model of serum anti-mullerian hormone from conception to menopause. PLoS ONE. 2011;6(7):e22024. https:\/\/doi.org\/10.1371\/journal.pone.0022024.","journal-title":"PLoS ONE"},{"issue":"12","key":"1087_CR3","doi-asserted-by":"publisher","first-page":"4650","DOI":"10.1210\/jc.2012-1440","volume":"97","author":"S Lie Fong","year":"2012","unstructured":"Lie Fong S, Visser JA, Welt CK, et al. Serum anti-mullerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood. J Clin Endocrinol Metab. 2012;97(12):4650\u20135. https:\/\/doi.org\/10.1210\/jc.2012-1440.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1087_CR4","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.rbmo.2015.06.015","volume":"31","author":"R Fleming","year":"2015","unstructured":"Fleming R, Seifer DB, Frattarelli JL, Ruman J. Assessing ovarian response: antral follicle count versus anti-Mullerian hormone. Reprod Biomed Online. 2015;31(4):486\u201396. https:\/\/doi.org\/10.1016\/j.rbmo.2015.06.015.","journal-title":"Reprod Biomed Online"},{"issue":"3","key":"1087_CR5","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/s0015-0282(01)03201-0","volume":"77","author":"DB Seifer","year":"2002","unstructured":"Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril. 2002;77(3):468\u201371. https:\/\/doi.org\/10.1016\/s0015-0282(01)03201-0.","journal-title":"Fertil Steril"},{"issue":"2","key":"1087_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ajog.2017.02.027","volume":"217","author":"R Tal","year":"2017","unstructured":"Tal R, Seifer DB. Ovarian reserve testing: a user\u2019s guide. Am J Obstet Gynecol. 2017;217(2):129\u201340. https:\/\/doi.org\/10.1016\/j.ajog.2017.02.027.","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"1087_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4103\/jhrs.JHRS_15_16","volume":"10","author":"R Vembu","year":"2017","unstructured":"Vembu R, Reddy NS. Serum AMH Level to Predict the Hyper Response in Women with PCOS and Non-PCOS Undergoing Controlled Ovarian Stimulation in ART. J Hum Reprod Sci. 2017;10(2):91\u20134. https:\/\/doi.org\/10.4103\/jhrs.JHRS_15_16.","journal-title":"J Hum Reprod Sci"},{"issue":"2","key":"1087_CR8","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.fertnstert.2017.10.021","volume":"109","author":"R Tal","year":"2018","unstructured":"Tal R, Seifer DB, Wantman E, Baker V, Tal O. Antimullerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012\u20132013. Fertil Steril. 2018;109(2):258\u201365. https:\/\/doi.org\/10.1016\/j.fertnstert.2017.10.021.","journal-title":"Fertil Steril"},{"issue":"6","key":"1087_CR9","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/humupd\/dmu062","volume":"21","author":"S Iliodromiti","year":"2015","unstructured":"Iliodromiti S, Anderson RA, Nelson SM. Technical and performance characteristics of anti-Mullerian hormone and antral follicle count as biomarkers of ovarian response. Hum Reprod Update. 2015;21(6):698\u2013710. https:\/\/doi.org\/10.1093\/humupd\/dmu062.","journal-title":"Hum Reprod Update"},{"issue":"6","key":"1087_CR10","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.fertnstert.2018.01.039","volume":"109","author":"BM Lyttle Schumacher","year":"2018","unstructured":"Lyttle Schumacher BM, Jukic AMZ, Steiner AZ. Antimullerian hormone as a risk factor for miscarriage in naturally conceived pregnancies. Fertil Steril. 2018;109(6):1065-1071 e1. https:\/\/doi.org\/10.1016\/j.fertnstert.2018.01.039.","journal-title":"Fertil Steril"},{"key":"1087_CR11","doi-asserted-by":"publisher","unstructured":"Cornille AS, Sapet C, Reignier A, et al. Is low anti-Mullerian hormone (AMH) level a risk factor of miscarriage in women <37 years old undergoing in vitro fertilization (IVF)? Hum Fertil (Camb) 2021:1\u201311. https:\/\/doi.org\/10.1080\/14647273.2021.1873431.","DOI":"10.1080\/14647273.2021.1873431"},{"issue":"3","key":"1087_CR12","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.fertnstert.2009.11.002","volume":"94","author":"R Hart","year":"2010","unstructured":"Hart R, Doherty DA, Norman RJ, et al. Serum antimullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS). Fertil Steril. 2010;94(3):1118\u201321. https:\/\/doi.org\/10.1016\/j.fertnstert.2009.11.002.","journal-title":"Fertil Steril"},{"issue":"1","key":"1087_CR13","doi-asserted-by":"publisher","first-page":"59 e1","DOI":"10.1016\/j.ajog.2014.02.026","volume":"211","author":"R Tal","year":"2014","unstructured":"Tal R, Seifer DB, Khanimov M, Malter HE, Grazi RV, Leader B. Characterization of women with elevated antimullerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. Am J Obstet Gynecol. 2014;211(1):59 e1-68. https:\/\/doi.org\/10.1016\/j.ajog.2014.02.026.","journal-title":"Am J Obstet Gynecol"},{"key":"1087_CR14","unstructured":"CDC. Centers for Disease Control and Prevention. 2019 Assisted Reproductive Technology Fertility Clinic and National Summary Report. 2021."},{"key":"1087_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12958-015-0134-9","volume":"13","author":"A Dumont","year":"2015","unstructured":"Dumont A, Robin G, Catteau-Jonard S, Dewailly D. Role of Anti-Mullerian Hormone in pathophysiology, diagnosis and treatment of Polycystic Ovary Syndrome: a review. Reprod Biol Endocrinol. 2015;13:137. https:\/\/doi.org\/10.1186\/s12958-015-0134-9.","journal-title":"Reprod Biol Endocrinol"},{"issue":"5","key":"1087_CR16","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s11596-018-1954-6","volume":"38","author":"XL Li","year":"2018","unstructured":"Li XL, Huang R, Fang C, Liang XY. Basal Serum Anti-Mullerian Hormone Level as a Predictor of Clinical Outcomes in Freezing-all Embryo Transfer Program. Curr Med Sci. 2018;38(5):861\u20137. https:\/\/doi.org\/10.1007\/s11596-018-1954-6.","journal-title":"Curr Med Sci"},{"issue":"3","key":"1087_CR17","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/humrep\/deaa008","volume":"35","author":"P Peuranpaa","year":"2020","unstructured":"Peuranpaa P, Hautamaki H, Halttunen-Nieminen M, Hyden-Granskog C, Tiitinen A. Low anti-Mullerian hormone level is not a risk factor for early pregnancy loss in IVF\/ICSI treatment. Hum Reprod. 2020;35(3):504\u201315. https:\/\/doi.org\/10.1093\/humrep\/deaa008.","journal-title":"Hum Reprod"},{"issue":"6","key":"1087_CR18","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/humupd\/dmab018","volume":"27","author":"A Busnelli","year":"2021","unstructured":"Busnelli A, Somigliana E, Cirillo F, Levi-Setti PE. Is diminished ovarian reserve a risk factor for miscarriage? Results of a systematic review and meta-analysis. Hum Reprod Update. 2021;27(6):973\u201388. https:\/\/doi.org\/10.1093\/humupd\/dmab018.","journal-title":"Hum Reprod Update"},{"issue":"9","key":"1087_CR19","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1210\/clinem\/dgab168","volume":"106","author":"R Tal","year":"2021","unstructured":"Tal R, Seifer DB, Tal R, Granger E, Wantman E, Tal O. AMH Highly Correlates With Cumulative Live Birth Rate in Women with Diminished Ovarian Reserve Independent of Age. J Clin Endocrinol Metab. 2021;106(9):2754\u201366. https:\/\/doi.org\/10.1210\/clinem\/dgab168.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1087_CR20","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.fertnstert.2017.07.001","volume":"108","author":"B Tarasconi","year":"2017","unstructured":"Tarasconi B, Tadros T, Ayoubi JM, Belloc S, de Ziegler D, Fanchin R. Serum antimullerian hormone levels are independently related to miscarriage rates after in vitro fertilization-embryo transfer. Fertil Steril. 2017;108(3):518\u201324. https:\/\/doi.org\/10.1016\/j.fertnstert.2017.07.001.","journal-title":"Fertil Steril"},{"issue":"2","key":"1087_CR21","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.rbmo.2019.04.004","volume":"39","author":"E Leclercq","year":"2019","unstructured":"Leclercq E, de Saint ML, Bohec C, et al. Blood anti-Mullerian hormone is a possible determinant of recurrent early miscarriage, yet not conclusive in predicting a further miscarriage. Reprod Biomed Online. 2019;39(2):304\u201311. https:\/\/doi.org\/10.1016\/j.rbmo.2019.04.004.","journal-title":"Reprod Biomed Online"},{"issue":"2","key":"1087_CR22","first-page":"76","volume":"2","author":"HB Ford","year":"2009","unstructured":"Ford HB, Schust DJ. Recurrent pregnancy loss: etiology, diagnosis, and therapy. Rev Obstet Gynecol. 2009;2(2):76\u201383 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19609401.","journal-title":"Rev Obstet Gynecol"},{"issue":"9","key":"1087_CR23","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.3390\/jcm9092700","volume":"9","author":"D Mayrhofer","year":"2020","unstructured":"Mayrhofer D, Hager M, Walch K, et al. The Prevalence and Impact of Polycystic Ovary Syndrome in Recurrent Miscarriage: A Retrospective Cohort Study and Meta-Analysis. J Clin Med. 2020;9(9):2700. https:\/\/doi.org\/10.3390\/jcm9092700.","journal-title":"J Clin Med"}],"container-title":["Reproductive Biology and Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-023-01087-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12958-023-01087-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-023-01087-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T08:18:25Z","timestamp":1680682705000},"score":1,"resource":{"primary":{"URL":"https:\/\/rbej.biomedcentral.com\/articles\/10.1186\/s12958-023-01087-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1087"],"URL":"https:\/\/doi.org\/10.1186\/s12958-023-01087-5","relation":{},"ISSN":["1477-7827"],"issn-type":[{"value":"1477-7827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"assertion":[{"value":"1 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Exempted from review by the institutional review board of Yale School of Medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}